poisar

Stocks · News reference

Yarrow Bioscience And VYNE Therapeutics Compete Merger With Previously Announced Private Financings Totaling ~$200M; To Operate As Yarrow Bioscience And Trade On Nasdaq Capital Market From July 28 Under Ticker Symbol 'YARW'

Benzinga Newsdesk

Yarrow is advancing YB-101—a potential first-in-class anti-TSHR antibody, designed to directly disrupt the central mechanism driving both Graves’ disease ("GD") and thyroid eye disease ("TED")Dosing

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

VYNE
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGAR

    8-K/A filing — Yarrow Bioscience, Inc. (VYNE)

    Filed: 2026-08-13 AccNo: 0001104659-26-095925 Size: 8 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

    VYNE
  2. SEC EDGAR

    8-K filing — Yarrow Bioscience, Inc. (VYNE)

    Filed: 2026-07-28 AccNo: 0001104659-26-087601 Size: 15 MB Item 1.01: Entry into a Material Definitive Agreement Item 2.01: Completion of Acquisition or Disposition of Assets Item 2.02: Results of Operations and Financial Condition Item 3.02: Unregistered Sales of Equity Securities Item 3.03: Material Modifications to Rights of Security Holders Item 5.01: Changes in Control of Registrant Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 5.05: Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

    VYNE